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Patients with severe refractory asthma present a challenging clinical conundrum for practising 68 
clinicians. Biologics that target key mediators in the type 2 (T2) inflammation cascade, including IL-4, 69 
IL-5, IL-13 and IgE, can be effective strategies for these patients. However, with various biologics 70 
available, choosing the optimal one for a particular patient becomes a nuanced decision. We 71 
propose a pragmatic algorithm which identifies the optimal biologic class for patients who have 72 
specific T2 disease endotypes. Patients with eosinophilic endotypes fare well with anti-IL5(rα) 73 
medications, comprising mepolizumab, benralizumab and reslizumab as they have been shown to 74 
reduce exacerbations in severe eosinophilic asthma by approximately 50%. In patients with FeNO-75 
high endotypes, anti-IL4rα such as dupilumab is deemed to be most effective and has demonstrated 76 
a 47% reduction in asthma exacerbations although a recent indirect treatment comparison suggests 77 
further promising results. For patients with severe uncontrolled allergic asthma, anti-IgE 78 
(omalizumab) is effective and has been shown to confer a 25% reduction in asthma exacerbations. 79 
T2 comorbidities including chronic rhinosinusitis with nasal polyps, atopic dermatitis, chronic 80 
idiopathic urticaria and eosinophilic esophagitis are important to bear in mind prior to the 81 
prescription of biologics. Further head-to-head studies are indicated to compare biologics in patients 82 
with mixed endotypes according to peripheral blood eosinophils, FeNO and allergic status. The 83 
evidence strongly supports endotype-driven prescribing of biologics in order to achieve clinically 84 
relevant outcomes in severe refractory asthma and related comorbidities. 85 
Word count 232 86 
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Patients with severe uncontrolled asthma present a challenging clinical conundrum for practising 91 
clinicians due to their requirement for extensive diagnostic evaluation, high consumption of 92 
healthcare resources and heavy symptom burden.
1
 Global Initiative for Asthma (GINA) defines 93 
severe asthma as uncontrolled despite adherence with maximal optimised therapy (step 4 or 5) and 94 
treatment of contributory factors, or that worsens when high dose treatment is decreased, affecting 95 
an estimated 3.7% of patients with asthma.  96 
Type 2 (T2) inflammation asthma is primarily driven by various cytokines including IL-4, IL-5, and IL-97 
13 and these in turn regulate the production of quantifiable biomarkers, namely IgE, eosinophils and 98 
fractional exhaled nitric oxide (FeNO) [figure 1]. It is thought that despite optimised inhaled 99 
corticosteroid (ICS) therapy many asthmatics have persistent airway T2 inflammation with this 100 
cohort of patients being older and having more severe disease.
2
 101 
This article is not intended to be an exhaustive systematic review, nor will it explore non-T2 asthma 102 
and the follow-up decisions surrounding biological therapies such as stopping and switching 103 
decisions, as these have already been covered in detail elsewhere.
3-6
 Instead its purpose is to provide 104 
a focussed pragmatic real-life practice guide for physicians based on current available guidance on 105 
biological therapies with particular reference to common T2 endotypes. This is admittedly a 106 
challenging feat as most of the evidence is based from trials that were restricted to a specific 107 
endotype appropriate to the molecular target of the treatment and/or had inconsistent eligibility 108 
criteria that excluded certain populations of interest.
7
  109 
It is always prudent to confirm the original asthma diagnosis.
8
 Secondly, optimisation of inhaler 110 
technique, medication adherence, and management of comorbidities, modifiable risk factors and 111 
psychosocial circumstances is mandatory. For severe uncontrolled asthma, discussion at a severe 112 
asthma multidisciplinary team (MDT) should occur as there is growing evidence that this significantly 113 
reduces asthma-related hospital admissions and hospital days.
9
 Indeed, our Tayside severe asthma 114 
MDT have meetings on a weekly basis.  115 
In patients with T2 asthma, monoclonal antibodies targeting immunoglobulin type E (IgE), 116 
interleukin 4 receptor alpha (IL4rα) and interleukin 5 (IL5) are attractive therapeutic options as they 117 
reduce exacerbation rate and oral corticosteroid (OCS) dose requirement, as well as improve quality 118 
of life, pulmonary function and symptom control to varying degrees (Table 1).
10-12
 This begs the 119 
question of which biologic is best suited to an asthmatic patient based on their particular disease 120 
endotype. Peripheral blood eosinophils (PBE), FeNO and allergic status are the most commonly 121 
utilised T2 biomarkers in clinical practice for assessing asthma and assisting in generating specialist 122 
decisions. Here we propose a simplified clinical algorithm to assist practising clinicians in 123 
determining the optimal biologic depending on the specific combination of T2 biomarkers in patients 124 
presenting with severe uncontrolled asthma based on common endotypes (figures 2 and 3).  125 
There is only one study where it is possible to estimate the relative prevalence of different T2 126 
endotypes as enrolment was independent of biomarkers. Here the relative prevalence of endotypes 127 
was shown to be 42% for PBE ≥150/µl, FeNO ≥25ppb; 30% in PBE ≥150/µl, FeNO <25ppb; and 9% in 128 
PBE <150/µl FeNO ≥25ppb; while the remaining 19% had PBE <150/µl and FeNO <25ppb.
13
 In 129 
essence, a large proportion (72%) of patients with severe asthma appear to have an eosinophilic 130 
endotype, albeit using a rather low cut point of ≥150/µl. This breakdown did not factor in the 131 
presence or absence of an allergic endotype. Furthermore, one recent retrospective observational 132 
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cohort analysis demonstrated that 34% of severe asthma patients have an eosinophilic endotype 133 
using the more clinically relevant cut-point of 300/µl.
14
  134 
Allergic asthma (defined as at least one positive allergen-specific test) is widely regarded as the most 135 
common endotype with a prevalence of around 56%.
15
 The Severe Asthma Research Program (SARP) 136 
study estimated that the proportion of severe asthma patients with a negative skin prick test varied 137 
between 17 and 34%,
16
 in keeping with the U-BIOPRED cohort’s approximation.
17
  138 
For the purposes of this review article, allergy in keeping with the Omazilumab label indication is 139 
defined as a total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen specific IgE ≥0.35 kU/L at 140 
baseline.
18
 However in real life clinical practice, our Tayside severe asthma multidisciplinary team 141 
(MDT) meeting would only designate a patient with a total serum IgE ≥100 IU/mL and ≥2 142 
aeroallergen specific IgE ≥0.35 kU/L or positive skin prick tests at baseline to be a clinically relevant 143 
allergic endotype.
19
 This definition is based on our regional experience that has been pragmatically 144 
adapted from clinical practice but we duly appreciate that most of the studies and evidence base use 145 
the former criteria for defining allergy. Similarly, we would only classify patients into an eosinophilic 146 
endotype if their PBE count exceeded 300/µl, ideally over 2 different time points in the preceding 6 147 
months. Clinicians should recognise that significant variability of blood eosinophils in patients with 148 
severe asthma exists, further stressing the importance of repeat measurements over time for the 149 
appropriate allocation of therapeutic interventions.
20
 At this juncture it is also important to point out 150 
that the presence of raised FeNO is highly dependent on adherence to ICS therapy or the use of oral 151 
corticosteroids (OCS), both of which suppress FeNO. For the purpose of this review we will adopt a 152 
pragmatic cut off of ≥25ppb while taking ICS to denote a patient with a high FeNO endotype. 153 
Eosinophilic endotypes 154 
A recent Cochrane review indicates that the three anti-IL5(rα) agents – mepolizumab (MEPO), 155 
benralizumab (BENRA) and reslizumab (RESLI) – reduce rates of clinically significant asthma 156 
exacerbations by approximately 50% in patients with severe eosinophilic asthma on standard of 157 
care.
21
 Furthermore, they were shown to produce a small (80 – 110ml) but statistically significant 158 
improvement in forced expiratory volume in 1 second (FEV1), although it is perhaps worth noting 159 
that the minimum clinical important difference (MCID) is traditionally considered to be 230ml.
22
 160 
Patients also experienced modest improvements in their asthma control questionnaire (ACQ) and 161 
asthma quality of life questionnaire (AQLQ) but these were both also below the conventional MCID 162 
of 0.5.
23
 In the UK, the National Institute for Health and Care Excellence (NICE) guidance for MEPO 163 
and BENRA suggest at least 4 severe exacerbations needing systemic steroids along with PBE ≥300 164 
cells/µl in the past year or continuous OCS requirement over the previous 6 months. RESLI and 165 
BENRA are also indicated in UK for patients with PBE ≥400/µl and at least 3 exacerbations in the past 166 
12 months.  167 
The more common endotypes discussed in this article are depicted in figure 3: PBE-high, FeNO-high, 168 
allergic (endotype 1); PBE-high, FeNO-high, non-allergic (endotype 2); PBE-high, FeNO-low, non-169 
allergic (endotype 3); and PBE-low, FeNO-high and allergic (endotype 4). Patients with elevated PBE 170 
comprising endotypes 1-3 likely experience most benefit from anti-IL5(rα) therapy as eosinophilic 171 
proliferation, maturation and survival are governed by IL5.
24
 Exploratory modelling of baseline 172 
characteristics of patients in phase 3 studies support substantial reductions in the rate of severe 173 
exacerbations with MEPO in patients with higher PBE counts.
12, 25
 Likewise, higher PBE counts 174 




 Moreover, real world MEPO data suggests more impressive results compared to randomised 176 
controlled trials on reduction in exacerbations, hospitalisations along with an improvement in ACQ 177 
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score of 2.0 points at six months which far exceeds MCID of 0.5, although the placebo effect should 178 
be considered when interpreting these data.
28
  179 
Therefore, for any of the eosinophilic endotypes defined by PBE ≥300/µl, we would generally 180 
propose anti-IL5(rα) therapy as first line therapy unless there was a specific reason otherwise (figure 181 
2). This is based on the current evidence suggesting a higher exacerbation risk reduction with either 182 
anti-IL5(rα) (50%) or anti-IL4rα (47%) versus anti-IgE therapy (25%). Our tentative position here is 183 
that until there is good evidence showing reductions in airway eosinophilia from sputum or 184 
bronchial biopsy with anti-IL4rα, we would proffer a degree of caution in advocating dupilumab as 185 
equal first line therapy with anti-IL5(rα) for such patients despite similar reductions in exacerbations. 186 
The following discussion delves deeper into the individual eosinophilic endotypes and implications 187 
for biologic therapy. 188 
For endotype 1, any of the monoclonal antibodies directed against IL5(rα), IL4rα or IgE might in 189 
theory be considered equivalent first line options. However, currently available evidence seems to 190 
suggest a greater decrease in asthma exacerbation rates and OCS dose requirement in patients 191 
treated with anti-IL5(rα) or anti-IL4rα compared to those on anti-IgE.
11, 21, 29
 Therefore, in the 192 
absence of any defining comorbidities, our MDT would recommend anti-IL5(rα) or anti-IL4rα as first 193 
line, with anti-IgE as second line in patients with endotype 1 (figure 2). In real life clinical practice, 194 
the choice of biologic in patients with this endotype would rest upon physician experience and 195 
preference, informed patient choice, cost and presence of any other relevant comorbidities, which 196 
are explored in more detail later. For example, patients leading a busy life might prefer the 197 
convenience of taking maintenance therapy with BENRA every 8 weeks rather than dupilumab 198 
(DUPI) every 2 weeks. 199 
Similarly, for endotype 2, evidence seems to support that either anti-IL5(rα) or anti-IL4rα could be 200 
considered first line therapy. For instance, pooled analysis of the BENRA trials revealed that it 201 
maintains its effect on exacerbation reduction and lung function improvement for patients with SEA 202 
irrespective of allergic status.
30
 It is worth noting that in this analysis, allergy was defined with a 203 
perhaps more clinically relevant serum total IgE cut-off of ≥150 kU/L . 204 
To determine what actually constitutes clinically relevant eosinophilia, closer examination of a 205 
secondary analysis of the pivotal BENRA trials reveals a so-called sweet spot for exacerbation rate 206 
reduction and FEV1 improvement relative to placebo that appears to occur around PBE ≥300/µl
31
 207 
when plotted as a continuous variable. For instance, in the comparison between BENRA 30mg q8wk 208 
and placebo, patients with PBE ≥300/µl and ≥3 exacerbations in the prior year experienced a relative 209 
exacerbation rate reduction of 55% and FEV1 improvement of 252ml (above MCID of 230 ml). 210 
In a post-hoc analysis of the pivotal DUPI trials, using 200mg q2wk, exacerbations were reduced by 211 
68% in patients with PBE ≥150/µl, FeNO ≥25ppb as opposed to 33% in patients with PBE ≥150/µl, 212 
FeNO <25ppb.
32
 This infers that DUPI could potentially be more effective in patients with endotypes 213 
1 and 2 with high FeNO rather than those with endotype 3 with low FeNO. Unfortunately, no data 214 
were available for DUPI stratified at PBE ≥300/µl according to FeNO ≥25ppb vs <25ppb which in our 215 
opinion would have been more informative. Prospective head to head trials would be required to 216 
assess whether anti-IL4rα or anti-IL5(rα) is more effective first line treatment for patients with both 217 
FeNO ≥25ppb and PBE ≥300/µl in endotypes 1 and 2. In the same post-hoc analysis for patients on 218 
MEPO with PBE ≥150/µl, exacerbation rate was reduced by 62% for FeNO ≥25ppb but only 36% for 219 
<25ppb.
32
 MEPO also resulted in modest FEV1 improvements (122ml for ≥25 ppb and 101ml for 220 
<25ppb) in patients with PBE ≥150/µl, albeit this was below MCID.
22
 For patients on MEPO with PBE 221 
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≥300/µl the exacerbation rate reduction was 62% for FeNO ≥25ppb and 53% for <25ppb, in keeping 222 
with the lack of effect of IL5 signalling on FeNO. 223 
For endotype 3 i.e. PBE-high, FeNO-low and non-allergic, one might not expect patients to 224 
experience significant benefit from anti-IL4rα therapy as it acts on both IL4 and IL13, the latter of 225 
which regulates FeNO.
33
 However, the aforementioned data
32
 still implied a 33% reduction in 226 
exacerbation rate which might be clinically worthwhile. A key limitation here is the absence of 227 
available data for patients on DUPI with PBE ≥300/µl according to FeNO ≥ or <25ppb. Nonetheless in 228 
the primary analysis
11
 DUPI 300mg q2wk produced a 67% exacerbation reduction in those with PBE 229 
≥300/µl irrespective of FeNO, perhaps supporting a recommendation that both anti-IL5(rα) or anti-230 
IL4rα therapy may be considered as suitable first line options for endotypes 1, 2 and 3. 231 
Despite the promising results seen with anti-IL5(rα) therapy, recent data suggests that 43% of 232 
patients who fulfil the current approved treatment criteria are so-called suboptimal responders.
34
 233 
Sputum analysis in this subset of patients suggests a possible underlying autoimmune mediated 234 
aetiology related to the presence of anti-eosinophil peroxidase IgG, with a caveat that further 235 
evaluation is required before this can be considered as part of routine practice.  236 
FeNO-high endotypes 237 
In addition to endotypes 1 and 2, the FeNO-high endotype also includes patients with the PBE-low, 238 
FeNO-high, allergic endotype 4. Patients with either of these three FeNO-high endotypes would in 239 
theory be expected to have a favourable response to anti-IL4rα therapy as FeNO is closely regulated 240 
by IL13,
33
 however the results of the pivotal trials with tralokinumab and lebrikizumab which block 241 
IL13 signalling were equivocal.
35, 36
 This in turn suggests that blocking signalling of both IL4 and IL13 242 
with dupilumab is required to improve asthma control.
37
 243 
In the post-hoc analysis of the pivotal DUPI trials, exacerbations were reduced by 39% in patients 244 
with PBE <150/µl, FeNO ≥25ppb.
32
 Although not statistically significant due to small sample size, this 245 
finding contrasted the absence of therapeutic effect seen with MEPO in this endotype where there 246 
was only a 6% reduction. Intriguingly, in an exploratory post-hoc analysis of DUPI 300mg q2wk
11
 for 247 
patients with PBE ≥150/µl, FeNO <25ppb there appeared to be discordance in terms of a significant 248 
reduction in exacerbations but no improvement in FEV1 relative to placebo, whilst in patients with 249 
PBE <150/µl, FeNO ≥25ppb effects of DUPI were concordant on both exacerbations and FEV1. In 250 
another post-hoc analysis DUPI showed equivalent efficacy in allergic and non-allergic asthma,
18
 251 
although the definition of allergy was tenuously based on total serum IgE ≥30 IU/mL and ≥1 252 
perennial aeroallergen-specific IgE ≥0.35 kU/L. Notably, no comparison of response was made across 253 
a range of IgE cut points. Nevertheless, anti-IL4rα would be a suitable option for patients with 254 
endotype 4 as we appreciate that most of the studies commonly define allergy using these criteria. 255 
Taken together this clearly emphasises the importance of measuring both PBE and FeNO in severe 256 
asthma before making an informed decision regarding tailored biologic therapy. 257 
Although there are no head to head trials comparing various biologics for the treatment of common 258 
T2 asthma endotypes, a recent indirect treatment comparison using 14 randomised controlled trials 259 
demonstrated that DUPI was associated with a significantly greater reduction in annualised severe 260 
asthma exacerbation rate (26% greater reduction versus omalizumab (OMAL) and 28 – 54% versus 261 
anti-IL5(rα)).
38
 A 60 – 140ml improvement in FEV1 was also seen with DUPI versus the other biologics 262 
although this is below the MCID of 230ml.  263 
Allergic endotypes 264 
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Anti-IgE is a viable alternative for patients with endotypes 1 and 4 as a 2014 Cochrane review 265 
evaluating 25 randomised trials using OMAL demonstrated a 25% asthma exacerbation reduction as 266 
well as a significant ICS sparing effect.
29
 Humbert et al showed in a retrospective real life analysis 267 
that OMAL is an effective treatment option for severe allergic asthma irrespective of blood 268 
eosinophil count.
39
 Furthermore, post hoc analysis of an OMAL randomised controlled trial showed 269 
that lower baseline IgE concentrations were associated with a smaller benefit in exacerbation 270 
reduction and improvement in quality of life.
40
 In another prospective placebo controlled trial OMAL 271 
produced 39% greater relative exacerbation reduction in patients with FeNO ≥19.5ppb vs <19.5ppb 272 
and a 23% greater reduction comparing PBE ≥260/µl vs <260/µl.
41
 Although anti-IgE therapy is a 273 
suitable treatment for patients with endotypes 1 and 4, it may be desirable to consider the other 274 
biologics first based on current evidence. 275 
We wish to highlight that the PBE-low, FeNO-low, allergic endotype has deliberately been ommitted 276 
from figure 3 as in our clinical experience this is an uncommon clinical pattern. We would advocate 277 
an interval repeat measurement of PBE in such cases to exclude a false negative result. 278 
Treating T2 comorbidities 279 
When choosing the optimal biologic, the patient’s T2 endotype should be a key driver of clinical 280 
decision making (figures 2 and 3). However, prescribers should also take pre-existing comorbidities 281 
into account as there is a potential opportunity to treat two co-related T2 conditions. For example, 282 
MEPO is associated with marked decreases in PBE, oesophageal eosinophilia and improved clinical 283 
outcomes in patients with eosinophilic esophagitis (EE), although it does not have a licensed 284 
indication per se.
42
 DUPI also improves clinical outcomes in EE and reduces submucosal 285 
eosinophilia.
43
 Another example would be coexistent chronic rhinosinusitis and nasal polyposis 286 
(CRSwNP) which is associated with a better anti-asthmatic response to anti-IL5
44
 but does not 287 
appear to impact on nasal polyps per se at least using MEPO at licensed subcutaneous doses.
45
 This 288 
reiterates the importance of close monitoring of patients with dual pathology and frequent liaison 289 
between different specialties in the event of a disconnected response such as improvement in 290 
asthma but not CRSwNP. Patients with CRSwNP tend to have higher PBE which probably accounts 291 
for the enhanced anti-asthmatic response to anti-IL5 in the presence of this comorbidity. Since anti-292 
IL4rα has proven efficacy in CRSwNP
46
 it seems logical to use DUPI for patients with severe asthma 293 
especially where concomitant refractory upper airway disease is also present. If PBE is elevated 294 
above 1,000/µL along with other pertinent clinical features, then anti-myeloperoxidase and anti-295 
proteinase-3 antibodies should be measured to refute a diagnosis of eosinophilic granulomatosis 296 
with polyangiitis (EGPA), particularly if any other clinical features are present. Higher than currently 297 
licensed doses of MEPO have been shown to improve disease control in EGPA,
47
 and clinical trials are 298 
undergoing to evaluate benralizumab (NCT04157348). 299 
For patients with severe T2 asthma and concomitant atopic dermatitis (AD), anti-IL4rα is a logical 300 
option as it results in significant amelioration in disease severity and symptom burden in AD.
48
 301 
Finally, allergic asthmatic patients with concomitant refractory chronic idiopathic urticaria (CIU) 302 
should be trialled with anti-IgE therapy first as this has proven efficacy in both conditions.
10, 49
  303 
Further clinical considerations 304 
When determining T2 asthma endotype and making practical decisions on commencing biological 305 
therapies, we suggest using pragmatic FeNO and PBE thresholds of ≥25ppb and ≥300/µl respectively. 306 
Guideline recommendations for ICS-naïve patients advocate that FeNO >50ppb can be used to 307 
indicate eosinophilic inflammation and corticosteroid responsiveness.
50
 Nevertheless, we feel that 308 
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these cutpoints should be lower in patients taking ICS, for instance using FeNO ≥25 ppb.
51
 Caution 309 
should also be exercised when interpreting FeNO levels in the presence of comorbidities. For 310 
example, one prospective study of severe asthmatics confirmed elevated FeNO and PBE values in 311 
patients with nasal polyposis compared to to those without.
52
 312 
For anti-IL5(rα) in the UK, NICE proposes an optimal PBE threshold of ≥300/µl in keeping with the 313 
pooled analysis from the MEPO and BENRA trials
31, 53
 where PBE has been plotted as a continous 314 
variable for exacerbation reductions. The exception to this would be for patients who are taking 315 
maintenance OCS which markedly suppress PBE. 316 
In patients with raised FeNO clinicians should first of all consider treatment adherence or inhaler 317 
technique as low doses of ICS will usually suppress levels.
54, 55
 318 
A further clinical consideration is the relationship between peripheral blood and sputum eosinophil 319 
count, with more data becoming available to cast doubt on the traditionally presumed correlation.
56
 320 
A sputum eosinophil count of ≥3% is generally regarded as a raised value but in reality this has 321 
relatively little relevance in real life clinical practice as most clinicians do not perform induced 322 
sputum. Furthermore, some clinicians advocate a disconnect between peripheral blood and sputum 323 
eosinophil counts in patients with more severe asthma taking a higher ICS dose.
57
 For example 1mg 324 
of inhaled fluticasone proprionate has the equivalent  PBE suppressive effect as 5mg of oral 325 
prednisolone in adult asthma.
58
 Preliminary data suggest that FeNO >50ppb along with PBE ≥300/µl 326 
is associated with an 80% probability of a sputum eosinophilia ≥3%.
59
 In another study, FeNO was 327 
predictive of sputum eosinophilia at a cut-off point of 36ppb with a sensitivity of 67% and a 328 
specificity of 74%, whilst for blood eosinophils at a threshold of 113/µl the sensitivity was 62% and 329 
specificity was 78%.
60
 This might be important because the vast majority of asthma patients with 330 
sputum eosinophilia have mucous plugging present on HRCT.
61
 331 
Conclusions  332 
Ultimately the choice of biologic can be determined after careful consideration of the particular 333 
endotype, comorbidities and the existing clinical data as well as relative cost, dosing interval and 334 
availability of self injection (table 1). Our clinical experience from the MDT suggests that anti-IL5(rα) 335 
is a preferred therapeutic option for patients with SEA irrespective of FeNO or allergic status at least 336 
for patients with PBE ≥300/µl. A recent indirect treatment comparison of licensed doses showed 337 
that in asthmatic patients with similar PBE counts, MEPO was associated with significantly greater 338 
improvements in clinically significant exacerbations and asthma control compared to RESLI or 339 
BENRA,
62
 however this finding was not reproduced when a matching-adjusted comparison was 340 
made.
63
 There are real life data albeit preliminary to suggest that in patients who have failed on 341 
MEPO despite adequate PBE suppression, switching to BENRA may be associated with improved 342 
control,
64
 although it is conceivable that the same might equally apply to BENRA failures. Efficacy of 343 
anti-IL5(rα) seems to be unrelated to FeNO levels in those patients with high PBE.  344 
Although anti-IL4rα is most effective in patients with the high FeNO endotype, it also exhibits 345 
efficacy but to a lesser degree in patients with raised PBE and low FeNO. Until there is evidence to 346 
show that DUPI reduces bronchial submucosal or sputum eosinophilia, we would have reservations 347 
about using it in patients with PBE ≥1,000/µl since it may also raise PBE levels. Hypereosinophilia 348 
was reported in 4.1% of patients receiving DUPI compared to 0.6% receiving placebo.
11
 Although 349 
worsening clinical symptoms were only accompanied in 0.2% of overall patients with 350 
hypereosinophilia, one potential clinical challenge clinicians face is the next treatment decision for 351 
patients with rising PBE counts but improving asthma. Hence for patients with PBE ≥1,000/µl, our 352 
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MDT would suggest that until further long term safety data are available, anti-IL5(rα) seems to be 353 
the logical first line drug in such cases.  354 
The best evidence for OCS sparing is with using anti-IL5(rα) or anti-IL4rα rather than anti-IgE. Since 355 
anti-IL4rα suppresses IgE levels as well as FeNO we would advocate this over anti-IgE in patients with 356 
the FeNO-high, allergic endotype regardless of PBE status, especially as the magnitude of 357 
exacerbation reduction seems to be more impressive. Likewise, we would suggest using anti-IL5(rα) 358 
as first line rather than anti-IgE in patients with the PBE-high, allergic endotype irrespective of FeNO 359 
due to a greater reduction in exacerbations seen with the former.  360 
Ultimately head to head trials are urgently required to compare the different biologics across 361 
common type 2 endotypes, such as the PREDICTUMAB trial (NCT03476109) comparing MEPO and 362 
OMAL. We also look forward to more data becoming available on tezepelumab (TEZE) 363 
[NCT03927157], a monoclonal antibody directed against thymic stromal lymphopoietin, which has 364 
shown promising exacerbation reductions in phase 2.
65
 Since TEZE blocks signalling of the IL4, IL5 365 
and IL13 pathways and suppresses PBE, FeNO and IgE, one might consider this to be the most broad 366 
spectrum of current biologics.  367 
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Table 1: Effects of biologics on key patient outcomes and type 2 inflammatory biomarkers 
MAb Exac FEV1 ACQ/QoL OCS sparing PBE IgE FeNO 
Anti-IL5 +++ + + ++ +++ - - 
Anti-IL4rα +++ ++ + ++ - ++ ++ 
Anti-IgE ++ + + +/-* + +/-
# 
+ 
ACQ = asthma control questionnaire; Exac = exacerbations; FeNO = fractional exhaled nitric oxide; FEV1 = forced expiratory volume in 1 second; 
IgE = immunoglobulin type E; IL = interleukin; MAb = monoclonal antibody; PBE = peripheral blood eosinophils; QoL = quality of life; number of “+” 
symbols denotes degree of positive effect; *evidence for OCS sparing effect of Omalizumab is equivocal; ? = insufficient data; # Omalizumab 
paradoxically elevates bound total and specific IgE levels but reduces free IgE 
15 
 
Figure 1 legend 
Activation of T2 inflammation elevates levels of IgE, FeNO and PBE. These biomarkers are targeted 
by various biological therapies as depicted. Relationship between T2 inflammation with asthma and 
relevant comorbidities shown. AD – atopic dermatitis; AHR – airway hyperresponsiveness; AR – 
allergic rhinitis; ASM – airway smooth muscle; CIU – chronic idiopathic urticaria; CRSwNP – chronic 
rhinosinusitis with nasal polyps; EE – eosinophilic esophagitis; Exac – exacerbations; FeNO – 
fractional exhaled nitric oxide; IgE – immunoglobulin type E; IL – interleukin; PBE – peripheral blood 
eosinophils; Sympt – symptoms; T2 – type 2 inflammation. 
 
Figure 2 Legend  
Proposed pragmatic clinical decision-making algorithm for the management of uncontrolled severe 
refractory T2 asthma in relation to the current available biologics. FeNO – fractional exhaled nitric 
oxide; IL – interleukin; µl – microlitre; PBE – peripheral blood eosinophils; ppb – parts per billion 
 
Figure 3 Legend 
Commonly occurring patterns of Type 2 inflammation in relation to choosing optimal biological 
therapy for severe uncontrolled asthma. Numbering corresponds to the various endotypes referred 
to in manuscript text. * preferred for concomitant eosinophilic esophagitis; † preferred for 
concomitant chronic rhinosinusitis with nasal polyps or concomitant atopic dermatitis; ‡ preferred 
for concomitant chronic idiopathic urticaria; § comparable efficacy of anti-IL5(rα) and anti-IL4rα if 
PBE ≥150/µL; || Anti-IL4rα preferred over anti-IgE due to greater exacerbation rate reduction. Anti-
IL5(rα) preferred over anti-IL4rα for patients with endotypes 1, 2 and 3 if PBE ≥1,000/µl. PBE – 
peripheral blood eosinophils; FeNO – fractional exhaled nitric oxide. 
 



